Atomoxetine (Strattera) vs Adderall ADHD essay
You have a patient who is a new referral to you from the court system for substance abuse issues. This patient is a 32-year-old man who has a history of heroin abuse and bipolar II disorder. He began using heroin at age 19 and has been clean for the past 6 months.
He tells you that he was diagnosed with attention deficit hyperactivity disorder (ADHD) at age 11 and was prescribed Adderall. His drug use began at age 13 with smoking marijuana with friends and escalated from there. He was diagnosed with bipolar II disorder in his 20s but has never been hospitalized. His current medications include Suboxone 8 mg, risperidone 1 mg BID, Lamictal 200 mg daily, and Klonopin 1 mg TID PRN anxiety.
He meets with you and tells you he is committed to his sobriety and reports he is having a hard time at work. His attention and focus are poor, and he is at risk of losing, “the only job I could get after getting out of jail. I need this job because my fiancée has cancer and I have to support her three kids.” He tells you he was a patient at your clinic 10 years ago and was treated with Adderall by the psychiatrist at the time (during a period of sobriety). Once he relapsed, he stopped coming to the clinic and spiraled from there.
He tells you he was on Adderall IR 30 mg TID. He works 12-hour shifts and “needs to get through his shift” so he can provide for his family. He tells you he is not currently taking his Suboxone but does have it in case he has a craving for heroin.
Use the information above to address the following:
Given his substance abuse history, would you prescribe this patient Adderall IR?
Give an alternative treatment option. Why would this be a better option?
What dose would you use?
What steps can be taken to show adherence and prevent diversion?
Special Populations – Atomoxetine (Strattera) vs Adderall ADHD essay
Given his substance abuse history, would you prescribe this patient Adderall IR?
The patient has a history of opioid use disorder and bipolar II disorders, which necessitates careful assessment of risks, benefits, and safety considerations in managing the attention deficit hyperactivity disorder (ADHD). In this case, Adderall immediate release (IR) is not the most appropriate initial intervention. Given his extensive substance use history, current instability in recovery behaviors, and elevated risk for stimulant misuse and diversion. There is a concern in prescribing a stimulant (Adderall IT) as the patient presents several high-risk factors. He reports being sober from heroin for six months, but has been taking his prescribed buprenorphine/naloxone (Suboxone) inconsistently. This indicates partial non-adherence to the medication-assistant treatment. Independently discontinuing the prescribed Suboxone medication raises further concern for relapse vulnerability because medication-assisted treatment is linked with reduced overdose risk and improved opioid abstinence (Au et al., 2021). Besides that, the patient has a prior history that demonstrates a pattern in which taking prescribed stimulant treatment coincided with relapse and disengagement from care. Prescribing Adderall IR presents substantial potential for misuse because IR amphetamine formulations have a higher abuse liability owing to rapid onset and reinforcing effects (Tasman et al., 2024).
In addition, Adderall IR is a stimulant medication and may destabilize the patient’s mood as he has bipolar disorder, especially as the mood symptoms are not fully controlled. Although lamotrigine and risperidone are prescribed for the patient, there is a need to reassess his psychiatric stability before introducing a potent stimulant like Adderall IR. Contemporary evidence recommends cautious use of stimulants in individuals with co-occurring substance use disorders and bipolar disorder because the stimulants may precipitate substance relapse, impulsivity, or hypomania (Schatzberg & Nemeroff, 2024). As such, Adderall IR should not be prescribed as it creates unnecessary clinical and ethical risk.
Give an alternative treatment option. Why would this be a better option?
Atomoxetine (Strattera) is an appropriate alternative treatment option. It is a non-stimulant medication approved for treating ADHD. It has no euphoric properties and significantly lower potential for abuse when compared to Adderall and other amphetamine-based stimulants. This makes it a safer prescription option for patients with histories of substance use. A non-stimulant medication is recommended as an early-line or first-line agent in individuals with recent or active substance use disorders because it reduces diversion risk while improving attention, executive functioning, and occupational performance (Cheng & Boileau, 2025).
What dose would you use?
An appropriate starting dose for atomoxetine is 40 mg orally once daily for several days, with titration to 80 mg daily depending on clinical response and tolerance. It would be necessary to monitor for side effects such as mood changes, increased blood pressure, gastrointestinal upset, or insomnia. Psychoeducation regarding delayed medication onset should be provided as atomoxetine may take several weeks to achieve full therapeutic benefit. Additionally, the patient should be subjected to occupational support strategies, relapse prevention counseling, and cognitive behavioral therapy (CBT) for ADHD to complement the pharmacological treatment and improve overall outcomes (Cheng & Boileau, 2025).
What steps can be taken to show adherence and prevent diversion?
Steps can be taken to show adherence and prevent diversion. First, establish a controlled-substance treatment agreement that outlines the expectations regarding medication use, consequences of misuse, urine drug screening, and refill policies. Second, implement regular urine toxicology testing to monitor for illicit substances and verify adherence to the prescribed medications. Third, implement a prescription drug monitoring program (PDMP) that routinely identifies doctor shopping or duplicate prescriptions. Fourth, implement short prescription intervals with frequent follow-up visits to improve accountability and allow close assessment of mood stability, ADHD symptoms, and risk of relapse. Fifth, implement pill counts for controlled substances prescriptions. Finally, collaborate with addiction specialists and psychotherapy providers to strengthen continuity of care and support sustained recovery (Schatzberg & Nemeroff, 2024).
Overall, the substance use and complex psychiatric history necessitates a cautious, recovery-oriented approach. Adderall IR should be avoided, and instead select a non-stimulant option, such as atomoxetine, as it better prioritizes patient safety, reduces diversion risk, and supports long-term recovery while addressing ADHD symptoms.
References
Au, V. Y. O., Rosic, T., Sanger, N., Hillmer, A., Chawar, C., Worster, A., Marsh, D. C., Thabane, L., & Samaan, Z. (2021). Factors associated with opioid overdose during medication-assisted treatment: How can we identify individuals at risk?
Harm Reduction Journal, 18
(1), 71.
https://doi.org/10.1186/s12954-021-00521-4
Cheng, T., & Boileau, A. J. (2025). Effectiveness of Atomoxetine and Stimulant Combination in Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment: A Systematic Review.
Cureus, 17
(2), e79378.
https://doi.org/10.7759/cureus.79378
Schatzberg, A. F., & Nemeroff, C. B. (2024).
The American Psychiatric Association Publishing Textbook of Psychopharmacology
(6th ed.). American Psychiatric Association Publishing.
Tasman, A., Ng, C. H., Alfonso, C. A., Ndetei, D. M., Lecic-Tosevski, D., Riba, M. B., Alarcon, R. D., Kanba, S., & Schulze, T. G. (Eds.) (2024).
Tasman’s Psychiatry
(5th ed.). Wiley. Atomoxetine (Strattera) vs Adderall ADHD essay
Leave a Reply